Late breaking news e-poster presentation
Skeletal muscle-targeted therapies that increase contractility hold promise for the treatment of neuromuscular diseases. As a compound class, fast skeletal muscle troponin activators (FSTAs) directly increase muscle calcium (Ca ²+) sensitivity and amplify the muscle force response to subtetanic neural stimulation. Disease-modifying therapies like systemic gene transfer have previously been shown to improve muscle function in a canine model of myotubular myopathy. The purpose of the current study was to evaluate the expand ed utility of a canine skeletal muscle model to understand the pharmacokinetic/pharmacodynamic (PK/PD) relationship of the novel FSTA, CK-3762601.
Source: Neuromuscular Disorders - Category: Neurology Authors: Dr. Robert W Grange, Dr. Eva R Chin, Dr. Jordan Klaiman, Dr. Darren Hwee, Dr. Bradley Morgan, Dr. Fady Malik, Dr. Martin Childers, Dr. SiWei Luo, Dr. David Mack Source Type: research
More News: Brain | Calcium | Centronuclear Myopathies | Genetics | Jordan Health | Middle East Health | Neurology | Study